StreetInsider.com News Articles

Form SCHEDULE 13G/A Zentalis Pharmaceuticals Filed by: WALTERS GROUP

Wed, 19 Aug 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260819/26951382.html

Form SCHEDULE 13G/A Zentalis Pharmaceuticals Filed by: WALTERS GROUP

Wed, 19 Aug 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260819/26951382.html

Form 4 Zentalis Pharmaceuticals For: Aug 14 Filed by: WALTERS GROUP

Wed, 19 Aug 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260819/26951380.html

Form 4 Zentalis Pharmaceuticals For: Aug 14 Filed by: WALTERS GROUP

Wed, 19 Aug 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260819/26951380.html

Zentalis closes $92.6M public offering of common stock

Mon, 17 Aug 2026 16:01:14 -0400

Zentalis Pharmaceuticals (Nasdaq: ZNTL) closed an underwritten public offering of 26,450,000 shares of common stock at $3.50 per share, generating approximately $92.6 million in gross proceeds before deducting underwriting discounts, commissions, and offering expenses, according to a press release.

The share count includes 3,450,000 shares sold through the full exercise of the underwriters' option to purchase additional shares. All shares were sold by the company.

Zentalis said it intends to use the net proceeds, combined with existing cash, cash equivalents, and marketable securities, to fund clinical trials, preclinical studies, regulatory filings, manufacturing, and companion diagnostic development, as well as pre-commercial activities, capital

Zentalis closes $92.6M public offering of common stock

Mon, 17 Aug 2026 16:01:14 -0400

The share count includes 3,450,000 shares sold through the full exercise of the underwriters' option to purchase additional shares. All shares were sold by the company.

Zentalis closes $92.6M public offering of common stock

Mon, 17 Aug 2026 16:01:14 -0400

The share count includes 3,450,000 shares sold through the full exercise of the underwriters' option to purchase additional shares. All shares were sold by the company.

Zentalis closes $92.6M public offering of common stock

Mon, 17 Aug 2026 16:01:14 -0400

The share count includes 3,450,000 shares sold through the full exercise of the underwriters' option to purchase additional shares. All shares were sold by the company.

Zentalis closes $92.6M public offering of common stock

Mon, 17 Aug 2026 16:01:14 -0400

The share count includes 3,450,000 shares sold through the full exercise of the underwriters' option to purchase additional shares. All shares were sold by the company.

Zentalis closes $92.6M public offering of common stock

Mon, 17 Aug 2026 16:01:14 -0400

The share count includes 3,450,000 shares sold through the full exercise of the underwriters' option to purchase additional shares. All shares were sold by the company.

Zentalis closes $92.6M public offering of common stock

Mon, 17 Aug 2026 16:01:14 -0400

The share count includes 3,450,000 shares sold through the full exercise of the underwriters' option to purchase additional shares. All shares were sold by the company.

Zentalis closes $92.6M public offering of common stock

Mon, 17 Aug 2026 16:01:14 -0400

The share count includes 3,450,000 shares sold through the full exercise of the underwriters' option to purchase additional shares. All shares were sold by the company.

Zentalis closes $92.6M public offering of common stock

Mon, 17 Aug 2026 16:01:14 -0400

The share count includes 3,450,000 shares sold through the full exercise of the underwriters' option to purchase additional shares. All shares were sold by the company.

Zentalis closes $92.6M public offering of common stock

Mon, 17 Aug 2026 16:01:14 -0400

The share count includes 3,450,000 shares sold through the full exercise of the underwriters' option to purchase additional shares. All shares were sold by the company.

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares